[Comparative analysis of the financing of follow-up and rehabilitation care institutions and public mental health institutions: Application for innovative and expensive drugs]

Ann Pharm Fr. 2021 Nov;79(6):690-699. doi: 10.1016/j.pharma.2021.03.002. Epub 2021 Mar 11.
[Article in French]


Pharmacotherapeutic care is now expanding in public mental health institutions. Annual grants are funding the public psychiatric field, hindering access to therapeutic innovation and expensive medications due to long length of stay. On the threshold of the French Healthcare & Social Services Ministry "Ma Santé 2022" plan ("My Health 2022"), there is a risk of altering the continuum of care because of the complexity of the financing of certain high added value therapies. Despite a desire to adapt the system to meet constantly changing health needs, no actions have been taken to this date in psychiatry, with no funds being allocated for valuable medication, in contrary to follow-up care and rehabilitation structures, to our knowledge. This reinforces the discrepancy with the evolution of research, and further widens the gap in inequalities between health sectors. Optimising the funding of expensive medicines in psychiatry would make it possible to reduce the stranglehold of current allocations. Following the example of recent reforms in the follow-up care and rehabilitation structures, extra funds for high value-added therapies would make it possible to reduce complex medical decisions: from prevention to reintegration, patient care continuity would be vastly guaranteed.

Keywords: Financement; Follow-up care and rehabilitation; Funding; Hospital pharmacy; Mental healthcare; Médicaments onéreux; Pharmacie hospitalière; Santé mentale; Soins de suite et réadaptation; Value-added medications.

MeSH terms

  • Follow-Up Studies
  • Humans
  • Mental Health
  • Pharmaceutical Preparations*
  • Psychiatry*


  • Pharmaceutical Preparations